Merck & Co., which has been seeking U.S. approval for a successor to its withdrawn arthritis painkiller Vioxx for nearly three years, says it has given regulators new patient data about the drug, called Arcoxia, and expects a decision by April. Meanwhile, a Canadian court has authorized a class action brought on behalf of an undetermined number of Vioxx users from Quebec who claim using Vioxx harmed them. It is the first personal injury class action authorized to date in the mushrooming Vioxx litigation.
Merck Readies Vioxx Successor, Faces Class Suit in Canada
The Associated Press
November 14, 2006
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.